News Releases Year None202220212020 Tarsus Added to NASDAQ Biotechnology Index Dec 16, 2022 Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease Dec 15, 2022 Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements Nov 09, 2022 Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting Oct 25, 2022 Tarsus Announces Transition Plans for Board of Directors Oct 11, 2022 Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair Oct 06, 2022 Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis Sep 29, 2022 Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings Sep 27, 2022 Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis Sep 07, 2022 Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements Aug 11, 2022 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Presentations Tarsus Corporate Presentation February 2, 2023 Tarsus Saturn-2 Phase 3 Trial Topline Results Presentation May 4, 2022 Revolutionizing Treatment for Demodex Blepharitis Patients Webcast Presentation February 10, 2022